Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 0.58 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26530312 | 0.93 | MAOB (0.52) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL26527898 | 0.91 | ROCK2 (0.59) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL22165606 | 0.89 | ROCK2 (0.56) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL30292043 | 0.89 | ROCK2 (0.56) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL30292060 | 0.89 | ROCK2 (0.56) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL30292017 | 0.88 | MAOB (0.68) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL22165399 | 0.88 | MAOB (0.68) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL30292044 | 0.88 | MAOB (0.68) | ROCK2MAOBTP53POLBIMPDH2 | |
| SCHEMBL22165574 | 0.82 | MAOB (0.52) | ROCK2MAOBIMPDH2IMPDH1RPS6KB1 | |
| SCHEMBL30292072 | 0.82 | MAOB (0.52) | ROCK2MAOBIMPDH2IMPDH1RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ENDOGENA THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322749-A1 | NEW COMPOUNDS AND THEIR USE AS THERAPEUTICALLY ACTIVE SUBSTANCES IN THE TREATMENT AND/OR PREVENTION OF DISEASES INVOLVING THE RETINAL PIGMENT EPITHELIUM | ALDH1A2, NR2E3, RB1 | ROCK2 261/4885MAOB 972/4885TP53 3328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.